Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilars Rollout In India - BIO 2011 Conference

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON - Pfizer Inc. is all set to kick-off its journey into the world of biosimilars as it gives finishing touches to the launch of a range of insulins in India. The company is counting on a set of value propositions, high quality and competitive pricing to emerge as a "natural leader" in the Indian market
Advertisement

Related Content

Pfizer India Managing Director Kewal Handa On Drug Pricing, Patents And Access: An Interview With PharmAsia News (Part 2 of 2)
Pfizer’s Diminished Expectations For Insulin Biosimilar Market Likely Scuttled Partnership With Biocon
Pfizer’s Diminished Expectations For Insulin Biosimilar Market Likely Scuttled Partnership With Biocon
Is The Pfizer-Biocon Insulin Deal In Trouble? Some Say It May Be Off
Eli Lilly, Boehringer Ingelheim Combine Might To Push Brands As India's Diabetes Market Expands
Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
Biosimilar Insulin Worth The Effort? For Some, Maybe
With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market
With Biocon Deal, Pfizer Expects To Gain First Mover Advantage In Global Biosimilar Insulin Market
Pfizer Thinks Small: Partnership With Protalix On Gaucher Drug Eyes Cheaper Plant-Based Production
Advertisement
UsernamePublicRestriction

Register

SC078368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel